Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J.

Ther Drug Monit. 2004 Apr;26(2):137-44. Review.

PMID:
15228154
2.
3.

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Green AR, Cross AJ, Goodwin GM.

Psychopharmacology (Berl). 1995 Jun;119(3):247-60. Review.

PMID:
7675958
4.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

5.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
6.
8.

[Ecstasy--the status in French-speaking Switzerland. Composition of seized drugs, analysis of biological specimens and short review of its pharmacological action and toxicity].

Giroud C, Augsburger M, Sadeghipour F, Varesio E, Veuthey JL, Rivier L.

Praxis (Bern 1994). 1997 Mar 25;86(13):510-23. Review. French.

PMID:
9157497
9.

Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.

Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J.

Crit Rev Toxicol. 2012 Nov;42(10):854-76. doi: 10.3109/10408444.2012.725029. Epub 2012 Oct 3. Review.

PMID:
23030234
10.
11.

Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine.

Gudelsky GA, Yamamoto BK.

Methods Mol Med. 2003;79:55-73. Review.

PMID:
12506690
12.

Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity.

Parrott AC.

Pharmacol Biochem Behav. 2002 Apr;71(4):837-44. Review.

PMID:
11888574
13.

Ecstasy: are animal data consistent between species and can they translate to humans?

Easton N, Marsden CA.

J Psychopharmacol. 2006 Mar;20(2):194-210. Review.

PMID:
16510478
14.

Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F.

Mol Neurobiol. 2009 Jun;39(3):210-71. doi: 10.1007/s12035-009-8064-1. Epub 2009 Apr 17. Review.

PMID:
19373443
15.

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.

Gouzoulis-Mayfrank E, Daumann J.

J Psychopharmacol. 2006 Mar;20(2):188-93. Review.

PMID:
16510477
16.

Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation.

Seger D.

Clin Toxicol (Phila). 2010 Aug;48(7):695-708. doi: 10.3109/15563650.2010.516263. Review.

PMID:
20849328
17.

MDMA: interactions with other psychoactive drugs.

Mohamed WM, Ben Hamida S, Cassel JC, de Vasconcelos AP, Jones BC.

Pharmacol Biochem Behav. 2011 Oct;99(4):759-74. doi: 10.1016/j.pbb.2011.06.032. Epub 2011 Jul 5. Review.

PMID:
21756931
18.

MDMA (Ecstasy).

El-Mallakh RS, Abraham HD.

Ann Clin Psychiatry. 2007 Jan-Mar;19(1):45-52. Review.

PMID:
17453661
19.

Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings.

Pacifici R, Zuccaro P, Farré M, Pichini S, Di Carlo S, Roset PN, Palmi I, Ortuño J, Menoyo E, Segura J, de la Torre R.

Ann N Y Acad Sci. 2002 Jun;965:421-33. Review.

PMID:
12105117
20.

The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.

Monks TJ, Jones DC, Bai F, Lau SS.

Ther Drug Monit. 2004 Apr;26(2):132-6. Review.

PMID:
15228153
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk